May 8, 2012 – BB&T Capital Partners, through its second mezzanine fund, has invested subordinated debt to support the acquisition of SeraCare Life Sciences by Linden Capital Partners.
SeraCare serves the life sciences industry by providing products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The company’s portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. The company is based in Milford, MA (www.seracare.com).
BB&T Capital Partners manages over $725 million in committed capital across three fund strategies which are all focused on the middle market. The firm makes direct equity investments in control transactions of privately-held companies; provides subordinated debt or mezzanine capital in support of transactions led by financial sponsors and others; and invests in other private equity funds. The firm was founded in 1998 and is based in Winston-Salem, NC (www.bbtcp.com).
Linden Capital Partners is focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden’s strategy is based upon four elements: specialization on middle market healthcare and life science companies; integrated private equity and operating expertise; customized value creation programs for each portfolio company; and strategic relationships with large corporations. The firm is located in Chicago, IL (www.lindenllc.com).
